Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 1
2012 1
2013 3
2016 1
2017 1
2018 1
2019 4
2020 3
2021 6
2022 6
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Anticoagulant treatment of cancer-associated thromboembolism.
Mahé I, Mayeur D, Couturaud F, Scotté F, Benhamou Y, Benmaziane A, Bertoletti L, Laporte S, Girard P, Mismetti P, Sanchez O; INNOVTE CAT Working Group. Mahé I, et al. Among authors: mayeur d. Arch Cardiovasc Dis. 2024 Jan;117(1):29-44. doi: 10.1016/j.acvd.2023.11.010. Epub 2023 Nov 23. Arch Cardiovasc Dis. 2024. PMID: 38092578 Review.
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S. Galland L, et al. Among authors: mayeur d. Cancers (Basel). 2023 Feb 18;15(4):1299. doi: 10.3390/cancers15041299. Cancers (Basel). 2023. PMID: 36831640 Free PMC article. Review.
Trastuzumab-emtansine induced pleural and pericardial effusions.
Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A. Lombardi J, et al. Among authors: mayeur d. J Oncol Pharm Pract. 2021 Dec;27(8):2041-2044. doi: 10.1177/10781552211015772. Epub 2021 May 18. J Oncol Pharm Pract. 2021. PMID: 34000917
Population Pharmacokinetics of Palbociclib in aReal-World Situation.
Royer B, Kaderbhaï C, Fumet JD, Hennequin A, Desmoulins I, Ladoire S, Ayati S, Mayeur D, Ilie S, Schmitt A. Royer B, et al. Among authors: mayeur d. Pharmaceuticals (Basel). 2021 Feb 24;14(3):181. doi: 10.3390/ph14030181. Pharmaceuticals (Basel). 2021. PMID: 33668400 Free PMC article.
French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.
Bouvard B, Confavreux CB, Briot K, Bonneterre J, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Kerbrat P, Lespessailles E, Lesur A, Mayeur D, Paccou J, Trémollières F, Vieillard MH, Debiais F. Bouvard B, et al. Among authors: mayeur d. Joint Bone Spine. 2019 Oct;86(5):542-553. doi: 10.1016/j.jbspin.2019.07.005. Epub 2019 Jul 25. Joint Bone Spine. 2019. PMID: 31352137 Review.
French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, Vieillard MH, Debiais F. Briot K, et al. Among authors: mayeur d. Joint Bone Spine. 2019 Jan;86(1):21-28. doi: 10.1016/j.jbspin.2018.09.017. Epub 2018 Oct 1. Joint Bone Spine. 2019. PMID: 30287350 Review.
[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].
Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F; Groupe de travail du référentiel Association francophone pour les soins oncologiques de support (AFSOS) sur les nausées-vomissements induits par les traitements anti-cancéreux. Jovenin N, et al. Among authors: mayeur d. Bull Cancer. 2019 May;106(5):497-509. doi: 10.1016/j.bulcan.2019.02.002. Epub 2019 Mar 25. Bull Cancer. 2019. PMID: 30922554 Review. French.
34 results